Your Article Summary
See Latest ArticlesDifferences in psychometric properties, cut-off scores, and outcomes between the Barthel Index and Modified Rankin Scale in pharmacotherapy-based stroke trials: systematic literature review
Current Medical Research and Opinion, 06/26/09
Balu S - Despite the lack of uniformity in the cut-off points used in the trials, the follow-up time after administration of therapy, and the amount of time within which treatment is initiated after onset of stroke symptoms, the MRS seems to be more sensitive and responsive as compared to the BI in measuring stroke disability. However, more studies are required to differentiate the BI and the MRS that would help in selecting a scale that would appropriately capture outcomes among stroke patients.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/10/09
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/10/09
Fyi from human genome sciences: gsk initiates second pivotal phase 3 trial for investigational cardiovascular medication darapladib
Human Genome Sciences, 12/10/09
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Behavioral Dimensions and Acetylcholinesterase Inhibitor-related Effect in Alzheimer Disease Over Time: A Latent Trajectory Modeling
Cognitive and Behavioral Neurology, 12/10/09
Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid
Multiple Sclerosis, 12/10/09
Depression in Parkinson's Disease
Canadian Journal of Neurological Sciences, 12/10/09